Form 4: Maravai LifeSciences Director Sean Cunningham Acquires Restricted Stock Units

Director Sean Cunningham reports acquisition of restricted stock units in Maravai LifeSciences, held for the benefit of a GTCR-affiliated entity.

Summary

• On May 23, 2024, Sean Laurence Cunningham, a director of Maravai LifeSciences Holdings, Inc., acquired 20,645 shares of Class A Common Stock.
• These shares were granted as restricted stock units.
• The price of the stock was $10.78 per share.
• Following the transaction, Cunningham beneficially owns 48,916 shares.
• These securities are held for the benefit of a GTCR-affiliated entity, and Cunningham disclaims any pecuniary interest in them.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock units granted to a director. The director disclaims pecuniary interest, indicating the shares are held on behalf of another entity.

Positives

• The acquisition of restricted stock units by a director may signal confidence in the company's future performance.

Future Outlook

The restricted stock units vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Management Comments

• The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock, providing transparency to the market.

Stakeholder Impact

• The acquisition of restricted stock units by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates